GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mustang Bio Inc (NAS:MBIO) » Definitions » Earnings Yield (Joel Greenblatt) %
中文

Mustang Bio (Mustang Bio) Earnings Yield (Joel Greenblatt) % : -588.24% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Mustang Bio Earnings Yield (Joel Greenblatt) %?

Mustang Bio's Enterprise Value for the quarter that ended in Dec. 2023 was $8.71 Mil. Mustang Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-50.29 Mil. Mustang Bio's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2023 was -588.24%.

The historical rank and industry rank for Mustang Bio's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

During the past 9 years, the highest Earnings Yield (Joel Greenblatt) of Mustang Bio was 10000.00%. The lowest was -1739.72%. And the median was -38.72%.

MBIO's Earnings Yield (Joel Greenblatt) % is not ranked *
in the Biotechnology industry.
Industry Median: -15.615
* Ranked among companies with meaningful Earnings Yield (Joel Greenblatt) % only.

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Mustang Bio's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Mustang Bio Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Mustang Bio's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mustang Bio Earnings Yield (Joel Greenblatt) % Chart

Mustang Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only -37.74 -31.85 -135.14 3,333.33 -588.24

Mustang Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,333.33 -500.00 -172.41 -555.56 -588.24

Competitive Comparison of Mustang Bio's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Mustang Bio's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mustang Bio's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Mustang Bio's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Mustang Bio's Earnings Yield (Joel Greenblatt) % falls into.



Mustang Bio Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Mustang Bios Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-50.288/8.7113375
=-577.27 %

Mustang Bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-50.29 Mil.



Mustang Bio  (NAS:MBIO) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Mustang Bio Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Mustang Bio's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mustang Bio (Mustang Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
377 Plantation Street, Worcester, MA, USA, 01605
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors.
Executives
Fortress Biotech, Inc. 10 percent owner 1111 KANE CONCOURSE, SUITE 301, BAY HARBOR ISLANDS FL 33154
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Manuel Md Litchman director, officer: President and CEO 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10017
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Brian Achenbach officer: SVP, Fin. & Corp. Controller 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK NY 10014
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Adam J. Chill director 24 NEW ENGLAND EXECUTIVE PARK, SUITE 105, BURLINGTON MA 01803
Michael S Weiss director 750 LEXINGTON AVE, NEW YORK NY 10022
Michael J Zelefsky director
David J Horin officer: Interim CFO 1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020

Mustang Bio (Mustang Bio) Headlines

From GuruFocus